UPDATE: Deutsche Bank Reiterates Buy Rating, Raises PT on Gilead Sciences on Monthly HCV Market Model

Loading...
Loading...
In a report published Tuesday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on Gilead Sciences
GILD
, and raised the price target from $48.00 to $69.00. In the report, Karnauskas noted, “We built a monthly HCV market model and analyzed prior treatment trends to derive our estimates for 14,15-16, and 17+ as GILD plans to provide some color YE on these markets. Our conclusion is that SOF can sell WW $3.7B, $8.4B, $12.4B in 14, 15, and peak respectively. We analyzed the co's new HIV drug TAF and now include its impact in our model. Maintain Buy.” Gilead Sciences closed on Monday at $50.67.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsDeutsche Bank
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...